The Board of Directors of BOAN BIOTECH (06955) has been notified by its controlling shareholder, Luye Pharma Group, that pursuant to the terms of a subscription agreement related to exchangeable preferred shares, an arrangement has been made. Luye Pharma's wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., is scheduled to complete a proposed transfer by further placing 11.9866 million H shares in the market on January 27, 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments